Safety and efficacy of Immune checkpoint Inhibitors (ICIs) plus chemotherapy versus chemotherapy alone for small cell lung cancer (SCLC): A systematic review and meta-analysis of randomized controlled trials

Similar Items

• Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
  by: Caicun Zhou, et al.
  Published: (2020-10-01)
• Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer
  by: Guisen Yin, et al.
  Published: (2025-01-01)
• Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China
  by: Caicong You, et al.
  Published: (2024-12-01)
• CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
  by: Zhao Yang, et al.
  Published: (2020-10-01)
• Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
  by: Nobuyuki Yamamoto, et al.
  Published: (2020-05-01)